Adagene Inc. ADAG
1.48 USD -0.12 (-7.50%)
Regular-session close
1.48 0.00 0.00%
After hours · Nov 17, 4:00 PM ET
1.27 Day range 1.82
1.27 52-week range 4.85
- YTD
- -21.69%
- 1 year
- -18.68%
News
benzinga.com City Of Hope And Adagene Launch Phase 1 Clinical Trial To Explore Combination Therapy For Patients Battling Metastatic Colorectal Cancer Study was designed by medical oncologist to accelerate lifesaving care to patientsCity of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States,…
businesswire.com City of Hope and Adagene Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer LOS ANGELES & SAN DIEGO--(BUSINESS WIRE)--City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States, and Adagene Inc. (“Adagene”) (Nasdaq:…
globenewswire.com Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer Study designed by medical oncologist to accelerate lifesaving care to patients SAN DIEGO and LOS ANGELES, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven,…benzinga.com Adagene Announces Completion Of Patient Enrollment In Its Phase 2 Study Of Muzastotug To Treat Microsatellite Stable Colorectal Cancer Without Liver Metastases Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced completion of…
globenewswire.com Adagene Announces Completion of Enrollment in Randomized Dose Optimization Phase 2 Trial of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer - Enrollment of 60 patients complete; initial results expected in 1H 2027 to inform dose regimen for the Phase 3 trial - Adagene continues to own worldwide commercial rights to muzastotug SAN DIEGO…benzinga.com Adagene Doses First Patient In Phase 1 Study Evaluating Combination Of Muzastotug And INCA33890, Incyte’s TGFβR2 × PD-1 Bispecific Antibody, In Patients With Microsatellite Stable Colorectal Cancer Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte’s TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver…
globenewswire.com Adagene Announces Dosing of First Patient in Phase 1 Study of Muzastotug in Combination with Incyte's INCA33890 in Patients with Microsatellite Stable Colorectal Cancer Phase 1 study to evaluate the combination of muzastotug, a masked anti-CTLA-4 SAFEbody, and INCA33890, Incyte's TGFβR2 × PD-1 bispecific antibody, in 3L MSS CRC patients with and without liver…
globenewswire.com Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and…
marketbeat.com Adagene Eyes Phase II Data for Masked CTLA-4 Therapy in MSS Colorectal Cancer Adagene NASDAQ: ADAG is advancing its masked anti-CTLA-4 antibody, ADG126, also known as muzastotug, in metastatic microsatellite-stable colorectal cancer (MSS CRC) and in a neoadjuvant…
defenseworld.net Adagene (NASDAQ:ADAG) Stock Rating Reaffirmed as “Buy” by HC Wainwright Adagene (NASDAQ: ADAG - Get Free Report)'s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Monday, MarketBeat.com reports. They presently…
defenseworld.net Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts Adagene (NASDAQ: ADAG) Chairman, CEO and Co-Founder Peter Luo outlined the clinical-stage biotechnology company's antibody pipeline, its approach to masked therapies and upcoming development…
marketbeat.com Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts Adagene NASDAQ: ADAG Chairman, CEO and Co-Founder Peter Luo outlined the clinical-stage biotechnology company's antibody pipeline, its approach to masked therapies and upcoming development milestones…
globenewswire.com Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel…
globenewswire.com Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene's proprietary…
defenseworld.net Insider Buying: Adagene (NASDAQ:ADAG) CEO Acquires $63,913.50 in Stock Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) CEO Peter Luo acquired 20,290 shares of the business's stock in a transaction dated Wednesday, September 16th. The shares were acquired at…
seekingalpha.com Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
globenewswire.com Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept.
globenewswire.com Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and…
globenewswire.com Adagene to Participate in Three Upcoming Investor Conferences SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel…
globenewswire.com Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates Randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC) ongoing, with results expected in 1H 2027; potential registration trial expected in 2027 once recommended dose regimen…
zacks.com Adagene (ADAG) Upgraded to Buy: Here's What You Should Know Adagene (ADAG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com Are Medical Stocks Lagging Adagene (ADAG) This Year? Here is how Adagene Inc. Sponsored ADR (ADAG) and Contineum Therapeutics, Inc. (CTNM) have performed compared to their sector so far this year.
marketbeat.com Adagene Spotlights ADG126 Strategy as Masked CTLA-4 Trial Advances in Colorectal Cancer Adagene NASDAQ: ADAG Chief Strategy Officer Mickael Chane-Du outlined the company's clinical strategy for its lead antibody program, ADG126, during a discussion with Stifel senior biotech analyst…
